NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Hodgkin lymphoma
Hodgkin lymphoma · 8,920 new · 1,100 deaths (ACS 2026) · mortality 0.2 per 100k · 5-yr RS 89.3% (SEER)
Mortality 0.2 per 100k (SEER / ACS common-sites). Never an artboard percent.
Lifetime ≈ 0.2% (SEER Stat Facts). 240,775 people living with Hodgkin lymphoma in 2023. Stage uses Ann Arbor I–IV — not localized / regional / distant.
240,775 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.
Median age at diagnosis 38 · at death 72 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence men 2.8 / women 2.3 per 100k · mortality men 0.3 / women 0.2 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among people aged 20–34. Deaths highest among people aged 75–84. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases falling 1.3% each year (2014–2023). Death rates falling 3.1% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.
Highest new-case rate: Non-Hispanic White men 3.1 per 100k. Highest death rate: Hispanic men 0.4 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | 2.8 | 2.0 | 0.4 | 0.2 |
| Non-Hispanic American Indian/Alaska Native | 1.8 | 1.3 | — | — |
| Non-Hispanic Asian/Pacific Islander | 1.6 | 1.3 | 0.1 | 0.1 |
| Non-Hispanic Black | 3.0 | 2.2 | 0.3 | 0.2 |
| Non-Hispanic White | 3.1 | 2.6 | 0.3 | 0.2 |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
ACS early-detection pointer
ACS 2025 · People without Hodgkin lymphoma symptoms · ACS (2025): there are no widely recommended screening tests for Hodgkin lymphoma. No screening test has been shown to improve survival rates. Complementary to the encoded COG/ASCO chest-RT breast-imaging flag, which is not a Hodgkin incidence engine. Official percent-of-cases-by-stage cells are not restated.
Cited ACS statement only. Not a screening engine. ACS-hodgkin-detect
Surveillance pointer
COG-LTFU cited · encoded flag · COG Long-Term Follow-Up class after Hodgkin lymphoma. Years-out clock only. No invented relapse percent and no dose reconstruction.
Named public source only. Not a personal follow-up calendar. COG-LTFU
Surveillance pointer
ACS-hodgkin-follow 2025 · cited only · ACS after-treatment page names regular visits and tests after Hodgkin treatment, plus a survivorship care plan. Those months are not encoded. Complementary to the encoded COG years-out flag. No invented relapse percent.
Named public source only. Not a personal follow-up calendar. ACS-hodgkin-follow
Surveillance pointer
ACS-hodgkin-follow 2025 · cited only · ACS after-treatment page says most experts do not recommend any other testing to look for second cancers unless you have symptoms. ACS average-risk colorectal and lung guidelines are named, not encoded as extra Hodgkin screens. Complementary to the encoded COG years-out flag and the ACS living-as row. Not a second-primary screening engine. Official Stage I percent-of-cases cells are not restated.
Named public source only. Not a personal follow-up calendar. ACS-hodgkin-follow
Surveillance pointer
ACS-hodgkin-follow 2025 · cited only · ACS after-treatment page says anyone who got radiation to the neck or upper chest should have thyroid function checked with blood tests at least once a year. That yearly lab is named, not encoded. Neck-field radiation is linked to stroke risk; ultrasound of the neck vessels is named, not encoded. Complementary to the encoded COG years-out flag and the ACS living-as / second-cancer rows. Official Stage I percent-of-cases cells are not restated. Not a thyroid-lab or carotid-ultrasound engine.
Named public source only. Not a personal follow-up calendar. ACS-hodgkin-follow
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a yearly thyroid exam after head, neck, or throat radiation, lung function tests after some chemo or transplant, echoes after cardiotoxic chemo, and yearly mammograms plus breast MRIs after chest radiation before age 30. Those named tests are not encoded. Complementary to the lymphoma/myeloma printout and the COG / ASCO first row. Official Stage I percent-of-cases cells are not restated. Not an AML or PET/CT engine.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
ASCO-survivorship cited · encoded flag · COG / ASCO-class cardiomyopathy surveillance after anthracyclines, plus chest-RT late-effect flags. No cumulative doxorubicin-equivalent dose.
Named public source only. Flags are not dose reconstruction. ASCO-survivorship
Toxicity pointer
ACS-hodgkin-follow 2025 · empty on purpose · ACS after-treatment page names late and long-term side effects and second-cancer awareness after Hodgkin treatment. Those late effects are not encoded. Complementary to the encoded COG / ASCO flags. No dose reconstruction.
Named public source only. Flags are not dose reconstruction. ACS-hodgkin-follow
Toxicity pointer
ACS-hodgkin-follow 2025 · empty on purpose · ACS after-treatment page names later cancers after Hodgkin treatment. Those second-cancer risks are not encoded. Complementary to the encoded COG / ASCO flags. Official Stage I percent-of-cases cells are not restated. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-hodgkin-follow
Toxicity pointer
ACS-hodgkin-follow 2025 · empty on purpose · ACS after-treatment page names heart damage, low thyroid hormones, and loss of fertility as possible permanent effects. Doxorubicin heart damage may not show up until more than 10 years after treatment. Those effects are not encoded. Complementary to the encoded COG / ASCO flags. Official Stage I percent-of-cases cells are not restated. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-hodgkin-follow
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a yearly thyroid exam, lung function tests, echoes after cardiotoxic chemo, and yearly mammograms plus breast MRIs after chest radiation before age 30. Those named tests are not encoded. Official Stage I percent-of-cases cells are not restated. Complementary to the COG / ASCO first row. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
Late toxicity printout — Lymphoma / myeloma fields
Acute: ACS names fatigue, field skin change, sore throat, nausea, and low blood counts. Late: heart and lung problems after chest-field RT or named cardiotoxic or lung-toxic drugs, thyroid problems after neck-field RT, breast-imaging after chest RT, lasting fatigue, bowel or bladder problems after abdomen or pelvis treatment, hearing loss after high-dose platinum chemo, fertility effects, sexuality changes, neuropathy after chemo, and cognitive change after chemo. Monitor: COG / ASCO echo flags; yearly thyroid exam; lung function tests after some chemo or transplant; yearly mammograms plus breast MRIs after chest radiation before age 30; lasting fatigue or sleep problems; bowel or bladder change after abdomen or pelvis treatment; hearing change after high-dose platinum chemo; fertility after pelvis, belly, or spine treatment; sexuality or body-image change; numbness or tingling after chemo; memory, thinking, or focus change after chemo. Those names are not encoded. Hodgkin stays Ann Arbor. Official Stage I percent-of-cases cells are not restated. Anthracycline and bleomycin stay unnamed as myeloma-specific. Not an AML or PET/CT engine.
Anthracycline and bleomycin stay unnamed as myeloma-specific.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS long-term late names
ACS follow-up tests named here
Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Named conditions to monitor
Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS / COG / ASCO field names only. Complementary ACS long-term page is named, not encoded. Hodgkin stays Ann Arbor, not localized/regional/distant. No dose reconstruction. Official Stage I percent-of-cases cells are not restated.
Open Lymphoma / myeloma fields printout →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-hodgkin · guideline-only · evaluateHodgkinFlags · Hodgkin-COG-ASCO-flags
Ann Arbor — not localized / regional / distant
I 92.7% · II 95.4% · III 87.7% · IV 82.8%
Percent of cases by stage
Percent of cases by Ann Arbor stage is not encoded. Stage I on Stat Facts collides with a locked artboard figure.
lifetime
Hodgkin lymphoma birth-to-death
≈ 0.2%
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
flags only — no incidence %synthetic HL diagnosed at age 24 · 20 years out on this fixture · chest radiation flag · anthracycline flag
screening
Treatment-related breast screening after chest RT
COG/ASCO-class breast MRI + mammogram discussion after chest RT
on this plan
surveillance
Keep Lymphoma Away — follow-up after HL
Lymphoma follow-up stays on a specialist calendar — no invented relapse %
on this plan
toxicity
Anthracycline echo + chest-RT late effects
Echocardiogram flag (interval not computed)
on this plan
Noah · Plan — skin cancer
out of domainno Hodgkin diagnosis on this synthetic fixture
screening
Treatment-related breast screening after chest RT
out of domain
surveillance
Keep Lymphoma Away — follow-up after HL
out of domain
toxicity
Anthracycline echo + chest-RT late effects
out of domain
Walter · S1 prostate
out of domainno Hodgkin diagnosis on this synthetic fixture
screening
Treatment-related breast screening after chest RT
out of domain
surveillance
Keep Lymphoma Away — follow-up after HL
out of domain
toxicity
Anthracycline echo + chest-RT late effects
out of domain
Priya · average-risk
out of domainno Hodgkin diagnosis on this synthetic fixture
screening
Treatment-related breast screening after chest RT
out of domain
surveillance
Keep Lymphoma Away — follow-up after HL
out of domain
toxicity
Anthracycline echo + chest-RT late effects
out of domain
No Hodgkin incidence formula. Stage survival is Ann Arbor I 92.7 / II 95.4 / III 87.7 / IV 82.8 (all 89.3). 2023 prevalence 240,775.